General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.24 | N/A | N/A | N/A |
2024-03-14 | 2023-12 | -0.23 | N/A | N/A | N/A |
2023-11-09 | 2023-09 | -0.21 | N/A | N/A | N/A |
2023-08-09 | 2023-06 | -0.27 | N/A | N/A | N/A |
2023-05-09 | 2023-03 | -0.39 | N/A | N/A | N/A |
2023-03-09 | 2022-12 | -0.48 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-20 | Piper Sandler | Upgrade | Overweight | Overweight |
2023-07-04 | Oppenheimer | Downgrade | Outperform | Perform |
2023-05-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-05 | BROADFOOT JILL MARIE | Chief Financial Officer | 20.82K | Sale |
2023-04-25 | CLARKE JOHN K. | Director | 19.80K | Conversion of Exercise of derivative security |
2024-05-29 | COUGHLIN TIMOTHY P | Director | 0.00 | Purchase |
2024-06-04 | DENYES NANCY | General Counsel | 22.27K | Purchase |
2023-04-25 | GROSS JANE A | Director | 6.00K | Conversion of Exercise of derivative security |
2019-05-16 | KRUEGER NANCY | General Counsel | 25.35K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Federated Hermes, Inc. | 10.19M | 22.01M | 17.86% |
2023-06-29 | FMR, LLC | 8.14M | 17.59M | 14.28% |
2023-06-29 | Stonepine Capital Management, LLC | 4.63M | 9.99M | 8.11% |
2023-06-29 | Tikvah Management LLC | 2.46M | 5.32M | 4.31% |
2023-06-29 | Vanguard Group Inc | 2.30M | 4.97M | 4.03% |
2023-06-29 | Alyeska Investment Group, L.p. | 2.21M | 4.76M | 3.87% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-07-30 | Federated Hermes Kaufmann Small Cap Fund | 5.26M | 10.32M | 9.23% |
2023-07-30 | Federated Hermes Kaufmann Fund | 4.79M | 9.38M | 8.39% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 2.26M | 3.84M | 3.96% |
2023-08-30 | Fidelity Growth Company Fund | 2.06M | 3.50M | 3.61% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.57M | 3.39M | 2.75% |
2023-05-30 | Fidelity Growth Company K6 Fund | 687.02K | 1.56M | 1.20% |
Split | Date |
---|---|
1 : 14 | 2019-07-01 |
"During this quarter, we executed an agreement with United States Air Force Academy ("USAFA") for an initial amount of US$7.3million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. Our partnership with USAFA and the recent agreement execution will enable us to advance this program towards an Investigational New Drug ("IND")," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "Additionally, securing US patent coverage through at least 2039 for ATI-1501, our Metronidazole formulation, is a significant milestone leading up to the anticipated FDA Prescription Drug User Fee ("PDUFA") date on September 23, 2023. We look forward to receiving milestone payments and royalties from our partner, Saptalis Pharmaceuticals LLC ("Saptalis"), in the coming quarters based on their submission and commercialization plans. These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."
High on LIFE